2. Search Result
Search Result
Results for "

HLA-A*0201

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

15

Peptides

1

Natural
Products

44

Recombinant Proteins

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1780
    CEF20

    		CMV Infection
    CEF20 is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).
    CEF20
  • HY-P1780A
    CEF20 TFA

    		CMV Infection
    CEF20 TFA is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).
    CEF20 TFA
  • HY-P11084
    WT1 126-134 peptide

    		MHC Inflammation/Immunology Cancer
    WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .
    WT1 126-134 peptide
  • HY-P11379
    ELTLGEFLKL

    		Survivin MHC Inflammation/Immunology Cancer
    ELTLGEFLKL is a survivin peptide. ELTLGEFLKL shows significant stabilization of HLA-A*0201. ELTLGEFLKL can be used in the research of tumor immunotherapy .
    ELTLGEFLKL
  • HY-P1757
    HIV p17 Gag (77-85)

    		HIV Infection
    HIV p17 Gag (77-85) is an HLA-A*0201(A2)-restricted CTL epitope, used in the research of anti-HIV .
    HIV p17 Gag (77-85)
  • HY-P1881
    HPV16-E711-20 epitope

    		HPV Cancer
    HPV16-E711-20 epitope is a well-known HLA-A *0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .
    HPV16-E711-20 epitope
  • HY-P5478
    Influenza virus PA (46-54)

    		DNA/RNA Synthesis Influenza Virus Others
    Influenza virus PA (46-54) is a biological active peptide. (HLA-A*0201 restricted epitope from influenza virus RNA polymerase subunit, PA (46-54).)
    Influenza virus PA (46-54)
  • HY-P11434
    Adipophilin-derived peptide

    		MHC Cancer
    Adipophilin-derived peptide is a peptide derived from Adipophilin. Adipophilin-derived peptide binds to HLA-A*0201. Adipophilin-derived peptide can be used in cancer research .
    Adipophilin-derived peptide
  • HY-P5503
    Pol (476-484), HIV-1 RT Epitope

    		HIV Others
    Pol (476-484), HIV-1 RT Epitope is a biological active peptide. (This is a reverse transcriptase (RT) epitope (Pol residues 476-484). Within HIV-1 RT the peptide appears to be the dominant HLA A*0201-restricted epitope. Was used to investigate possible mechanisms behind HIV-1 escape from CTL. IV9 is the actual epitope processed and presented in HIV-1-infected cell lines.)
    Pol (476-484), HIV-1 RT Epitope
  • HY-P11084A
    WT1 126-134 peptide acetate

    		MHC Inflammation/Immunology Cancer
    WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide acetate is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide acetate/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide acetate can be used as a vaccine for T cells or as a target for antibodies .
    WT1 126-134 peptide acetate
  • HY-P11280A
    PRAME peptide (425-433) acetate

    		Melanocortin Receptor Cancer
    PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A*02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma .
    PRAME peptide (425-433) acetate
  • HY-106187B
    MART-1 (27-35) (human) TFA

    		Cancer
    MART-1 (27-35) (human) (TFA) is the amino acid fragment spanning positions 27 to 35 of the MART-1 protein, and it represents an immunogenic epitope recognizable by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TILs). MART-1 (27-35) (human) (TFA) can be used in studies related to melanoma .
    MART-1 (27-35) (human) TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: